Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Neoplasms 21Breast Neoplasms 19Triple Negative Breast Neoplasms 16Melanoma 15Urinary Bladder Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 13Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Solid Tumors 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Lymphoma 5Esophageal Neoplasms 5Stomach Neoplasms 4Lung Neoplasms 4Kidney Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Urologic Neoplasms 2Solid Tumor 2

Interventions

Gemcitabine 9Cisplatin 5vinflunine 4Carboplatin 4pembrolizumab 2enfortumab vedotin 2Ramucirumab 2Platinum 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1genexol-PM 1eribulin 1enzalutamide 1dehydroftorafur 1carotuximab 1avelumab 1atezolizumab 1abexinostat 1Vitamin D 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Molecular Diagnostic Techniques 1Mitozytrex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ureteral Neoplasms × atezolizumab × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡